Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA.

Ann Neurol. 2010 Jan;67(1):122-31. doi: 10.1002/ana.21843.

2.

Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects.

Apostolova LG, Morra JH, Green AE, Hwang KS, Avedissian C, Woo E, Cummings JL, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage. 2010 May 15;51(1):488-99. doi: 10.1016/j.neuroimage.2009.12.125.

3.

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ.

Lancet Neurol. 2010 Jan;9(1):119-28. doi: 10.1016/S1474-4422(09)70299-6.

4.

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW.

Neurology. 2010 Jan 19;74(3):201-9. doi: 10.1212/WNL.0b013e3181cb3e25.

5.

Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.

Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN.

Neurology. 2009 Dec 15;73(24):2079-85. doi: 10.1212/WNL.0b013e3181c679cc.

PMID:
20018636
6.
7.

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA.

Arch Neurol. 2009 Dec;66(12):1469-75. doi: 10.1001/archneurol.2009.269.

8.

Distinct brain networks in recognition memory share a defined region in the precuneus.

Dörfel D, Werner A, Schaefer M, von Kummer R, Karl A.

Eur J Neurosci. 2009 Nov;30(10):1947-59. doi: 10.1111/j.1460-9568.2009.06973.x.

PMID:
19895564
9.

White matter microstructure underlying default mode network connectivity in the human brain.

Teipel SJ, Bokde AL, Meindl T, Amaro E Jr, Soldner J, Reiser MF, Herpertz SC, Möller HJ, Hampel H.

Neuroimage. 2010 Feb 1;49(3):2021-32. doi: 10.1016/j.neuroimage.2009.10.067.

PMID:
19878723
10.

Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly.

Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA.

Biol Psychiatry. 2010 Mar 15;67(6):584-7. doi: 10.1016/j.biopsych.2009.08.024.

11.

Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease.

Henneman WJ, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM.

Neurology. 2009 Sep 22;73(12):935-40. doi: 10.1212/WNL.0b013e3181b879ac.

12.

Defining and labeling disease-modifying treatments for Alzheimer's disease.

Cummings JL.

Alzheimers Dement. 2009 Sep;5(5):406-18. doi: 10.1016/j.jalz.2008.12.003.

PMID:
19751920
13.

Is ApoE epsilon4 associated with cognitive functioning in African Americans diagnosed with Alzheimer Disease? An exploratory study.

Mount DL, Ashley AV, Lah JJ, Levey AI, Goldstein FC.

South Med J. 2009 Sep;102(9):890-3. doi: 10.1097/SMJ.0b013e3181b21b82.

14.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
15.

Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.

Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DE, Snyder CH, Alexander GE, Rademakers R, Reiman EM.

N Engl J Med. 2009 Jul 16;361(3):255-63. doi: 10.1056/NEJMoa0809437.

16.

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ.

Neurology. 2009 Sep 8;73(10):754-60. doi: 10.1212/WNL.0b013e3181b23564.

17.

Markers of Alzheimer's disease in a population attending a memory clinic.

Frisoni GB, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M, Gennarelli M, Binetti G, Bocchio L, Paghera B, Amicucci G, Bonetti M, Benussi L, Ghidoni R, Geroldi C.

Alzheimers Dement. 2009 Jul;5(4):307-17. doi: 10.1016/j.jalz.2009.04.1235.

PMID:
19560101
18.

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Bürger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K.

Lancet Neurol. 2009 Jul;8(7):619-27. doi: 10.1016/S1474-4422(09)70139-5.

PMID:
19523877
19.

Comparison of AdaBoost and support vector machines for detecting Alzheimer's disease through automated hippocampal segmentation.

Morra JH, Tu Z, Apostolova LG, Green AE, Toga AW, Thompson PM.

IEEE Trans Med Imaging. 2010 Jan;29(1):30-43. doi: 10.1109/TMI.2009.2021941.

20.

Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields.

Mueller SG, Weiner MW.

Hippocampus. 2009 Jun;19(6):558-64. doi: 10.1002/hipo.20614.

Items per page

Supplemental Content

Support Center